Anti-RSV F Protein Chimeric Monoclonal Antibody (Clone RSHZ19 (Felvizumab))

Respiratory syncytial virus (RSV) fusion (F) protein is a surface glycoprotein encoded by the F gene in RSV RNA. It is synthesized as an inactive precursor protein, F0, that undergoes proteolytic cleavage to release the F1 and F2 subunits, which are joined together by two disulfide bonds. Mature RSV F protein is composed of an N-terminal fusion peptide (FP), two heptad repeats (HRs), a transmembrane domain, and a cytoplasmic tail and assembles into homotrimers on the virus surface. Upon insertion of the FP in the target cell membrane, the HRs form a six-helical bundle (6-HB) that enables RSV to fuse with the target cell. RSV F protein is highly conserved between RSV subtypes A and B with approximately 90% amino acid identities. RSV is the most common causative agent of pediatric lower respiratory tract infections. Cayman's RSV F Protein Chimeric Monoclonal Antibody (Clone RSHZ19 (Felvizumab)) was produced recombinantly from the original humanized RSHZ19 antibody sequence, substituting the mouse antigen-binding domain with the rabbit IgG1 antigen-binding domain, and can be used for ELISA and in functional assays. The RSHZ19 antibody was generated by fusing human IgG1 constant domains to the antigen-binding domain of a mouse anti-RSV F protein monoclonal antibody.Synonyms: Respiratory Syncytial Virus F Protein, Respiratory Syncytial Virus Fusion Protein, RSV Fusion Protein. Immunogen: Recombinant human-targeted RSV F. Clone Designation: RSHZ19 (Felvizumab). Formulation: (Request formulation change), 200 µg of protein A-affinity purified monoclonal antibody. Storage Buffer: PBS with 0.02% ProClin(TM) 300. Host: Chimeric Monoclonal Antibody. Isotype: IgG1?. Applications: ELISA. Cross Reactivity: ((+)) F protein.